Thyroid transcription factor-1 (TTF-1) is a transcription factor that plays a role in the development and physiology of the thyroid and lungs. Expression of TTF-1 is used as a marker of lung and thyroid clinically. Commercially available clones of TTF-1 monoclonal antibodies, 8G7G3/1 and SPT24, have been reported to have different sensitivities for the detection of neoplasms of different origins. Although they are used extensively in daily practice, a comprehensive comparative study of these antibodies in a wide variety of neoplasms is lacking. We examined TTF-1 expression in primary tumors of the lung, prostrate, pancreas, stomach, salivary glands, breast, bladder, colon, and squamous cell carcinoma of the head and neck and compared the results obtained with both TTF-1 clones. The SPT24 clone detected more primary lung tumors of all histologic subtypes. Importantly, the SPT24 clone detected a significantly higher number of squamous cell carcinomas and carcinoid tumors of the lung. Among nonpulmonary primary tumors, a significant number of invasive urothelial carcinoma of the bladder (5.1%) was TTF-1 positive. In addition, a small proportion of prostate (1.2%), stomach (0.9%), salivary gland (1.8%), and colon (2.5%) carcinomas were positive with both clones. Of note, both clones stained the same nonpulmonary tumors with similar intensity and distribution. Carcinomas of the pancreas, breast, and squamous cell carcinomas of the head and neck were negative with both clones. In summary, the SPT24 clone detected a higher number of pulmonary non-small cell tumors of all histologic subtypes whereas both clones stained a similar proportion of nonpulmonary tumors.
Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Brown Medical School, Providence, RI
This project was supported by the Molecular Pathology Core of the COBRE Center for Cancer Research Development, NIH ♯P20 RR17695, awarded by the National Center for Research Resources, Institutional Development Award (IdeA) Program.
Reprints: Andres Matoso, MD, Department of Pathology and Laboratory Medicine, Rhode Island Hospital, APC12, 593 Eddy Street, Providence, RI 02903 (e-mail: firstname.lastname@example.org).
Received for publication June 29, 2009
accepted August 24, 2009
These findings were presented in part at the United States and Canadian Academy of Pathology Annual Meeting 2009, Boston, MA.
The authors state no conflict of interest.